Challenge | Solutions/options |
---|---|
Source and production methods | Bone marrow, umbilical cord, iPSC-derived |
Optimal dose (intravenous) | 2, 4, or 10 × 106/kg (ideal body weight) |
Number of doses and timing | One dose versus two doses Dose spacing 36–72 h apart? |
Inclusion criteria | High-flow nasal oxygen versus invasive mechanical ventilation |
Identifying treatment responsive phenotypes | Potential variables—age, viral, bacterial pneumonia, shock or not shock, biological variables (IL-8, Protein C, bicarbonate) |